Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06467370 · ClinicalTrials.gov registry record
A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 467
- Enrollment target
NCT06467370: Completed study, sponsored by Pfizer.
NCT06467370 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 467 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06467370 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 467 participants
- Enrollment target
Study Summary
This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely monoclonal antibodies targeting CGRP and onabotulinumtoxinA
Primary Outcome
Satisfaction with prescribed medication (rimegepant-treated attacks) as measured by 5 questions with a 7-point rating scale; Distribution analysis and Responder Yes/No. Responder definition: Extremely Satisfied, Satisfied, Slightly Satisfied."
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2025-03-11 |
What the finished NCT06467370 record still lists
NCT06467370 is an observational study that tracks outcomes without assigning an intervention. The registered 467 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06467370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06467370 about?
NCT06467370 is a clinical study titled "A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.". This study aims at characterizing the effectiveness of rimegepant as an acute migraine treatment in a real world setting on two aspects: * Consistency of response to rimegepant across multiple attacks * Effectiveness of rimegepant in users taking concomitant migraine preventive medications, namely ...
What is the current status of trial NCT06467370?
This trial is currently completed. The enrollment target is 467 participants. The study started on 2024-07-02. Estimated completion is 2025-03-11.
Who is sponsoring clinical trial NCT06467370?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06456554 · 467 participants · NA
Acellular Dermal Matrix Investigation in Breast Reconstruction
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI